BioLineRx Acquires Exclusive License Rights From Algen for Cancer Therapeutic BL-7030 JERUSALEM, May 17, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that it has acquired the rights to compound BL-7030, a novel molecule for targeted cancer therapy, from Algen, which...

BioLineRx Reacquires Rights to Leading Schizophrenia Drug Candidate BL-1020 JERUSALEM, May 11, 2011 (GLOBE NEWSWIRE) -- BioLineRx Ltd. (TASE:BLRX), a biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs or with advantages...

BioLineRx Receives Notice of Allowance From USPTO for Patent Covering BL-1020 Drug for Treatment of Schizophrenia JERUSALEM, April 4, 2011 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent...